NeRRe Therapeutics is developing orvepitant, a first-in-class NK-1 receptor antagonist, as a once-daily, innovative treatment for cough hypersensitivity disorders. After proving effective in patients with refractory or unexplained chronic cough, NeRRe is now advancing the treatment for chronic cough caused by idiopathic pulmonary fibrosis (IPF)—a rare and terminal progressive respiratory disease. A dominant symptom in many IPF patients is persistent, uncontrolled cough, which can be debilitating and for which there are no approved treatments. IPF has been recognized as an orphan disease both in Europe and the United States.
CEO
Mary Kerr
WEBSITE
https://www.nerretherapeutics.com/
INVESTED COMPANY
2021
DETAILS
NeRRe Therapeutics
Stevenage Bioscience Catalyst Incubator Building
Gunnels Wood Road, Stevenage, Herts, SG1 2FX
United Kingdom
